BA combined with EGFR-TKIs had a strong synergistic effect on inhibiting tumor proliferation (ZIP synergy score > 10), and the average proportions of the antitumor response attributable to BA combined with gefitinib/osimertinib were 25.052/26.043 in A549 cells and 28.457/20.256 in H1299 cells, indicating that these combinations had synergistic inhibitory effects. The gene discussed is EGFR; the disease is neoplasm.